Lisata Therapeutics, Valo Therapeutics enter preclinical research collaboration
The Fly

Lisata Therapeutics, Valo Therapeutics enter preclinical research collaboration

Lisata Therapeutics (LSTA) and Valo Therapeutics announced a preclinical research collaboration to investigate the benefits of combining Lisata’s novel product candidate, certepetide, with ValoTx’s platform technology, PeptiCRAd, and a checkpoint inhibitor in a melanoma mouse model. Under the agreement, ValoTx will be conducting the research, while Lisata will supply certepetide product.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App